EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.1.5 | medicine | the findings show that inflammation can supress NAT1, a key cellular defense enzyme, such a suppression may be implicated in drug toxicity and cancer risk | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.3.1.5 | cytokine | mixture of proinflammatory cytokines, interferon-gamma, interleukin-1beta, tumor necrosis factor-alpha | Homo sapiens | |
2.3.1.5 | proinflammatory cytokine | treatment of cholangiocarcinoma KKU-100 cells with cytokines (interferon-gamma, interleukin-1beta and tumor necrosis factor-alpha) suppresses NAT1 activity, reducing the Vmax without affecting the Km | Homo sapiens | |
2.3.1.5 | S-nitroso-glutathione | treatment of cholangiocarcinoma KKU-100 cells S-nitroso-glutathione results in reduced NAT1 activity as early as 2 h, and the suppression persists for 48 h | Homo sapiens |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.3.1.5 | 0.0028 | - |
p-Aminobenzoic acid | control | Homo sapiens | |
2.3.1.5 | 0.0028 | - |
p-Aminobenzoic acid | using control cholangiocarcinoma KKU-100 cells without cytokine administration, Vmax: 211.2 pmol/min/mg | Homo sapiens | |
2.3.1.5 | 0.0033 | - |
p-Aminobenzoic acid | cytokine mixture | Homo sapiens | |
2.3.1.5 | 0.0033 | - |
p-Aminobenzoic acid | using control cholangiocarcinoma KKU-100 cells after treatment with the mixture of inflammatory cytokines for 48 h, Vmax: 135.7 pmol/min/mg. A significant decrease in Vmax is shown but without affecting Km, implying a change in the amount of enzyme but not in its affinity | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.1.5 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.3.1.5 | cholangiocarcinoma cell | cytokine treatment and S-nitroso-glutathione treatment of cholangiocarcinoma KKU-100 cells induces a decreased NAT1 mRNA expression | Homo sapiens | - |
2.3.1.5 | KKU-100 cell | - |
Homo sapiens | - |
EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|---|
2.3.1.5 | 0.054 | - |
cytokine mixture, 2.5 microM p-aminobenzoic acid | Homo sapiens |
2.3.1.5 | 0.097 | - |
cytokine mixture, 7.5 microM p-aminobenzoic acid | Homo sapiens |
2.3.1.5 | 0.108 | - |
control, 2.5 microM p-aminobenzoic acid | Homo sapiens |
2.3.1.5 | 0.124 | - |
cytokine mixture, 40 microM p-aminobenzoic acid | Homo sapiens |
2.3.1.5 | 0.146 | - |
control, 7.5 microM p-aminobenzoic acid | Homo sapiens |
2.3.1.5 | 0.2 | - |
control, 40 microM p-aminobenzoic acid | Homo sapiens |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.5 | acetyl-CoA + p-aminobenzoic acid | - |
Homo sapiens | CoA + N-acetyl-4-aminobenzoic acid | - |
? | |
2.3.1.5 | acetyl-CoA + p-aminobenzoic acid | activity assay | Homo sapiens | CoA + N-acetyl-4-aminobenzoic acid | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.3.1.5 | arylamine N-acetyltransferase 1 | - |
Homo sapiens |
2.3.1.5 | NAT1 | - |
Homo sapiens |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
2.3.1.5 | 7.5 | - |
assay at | Homo sapiens |
2.3.1.5 | 7.5 | - |
activity assay | Homo sapiens |